[1]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15-18,58.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):15-18,58.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
点击复制

甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第1期
页码:
15-18,58
栏目:
出版日期:
2014-01-25

文章信息/Info

Title:
Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer
作者:
寇莹;  刘建中;  郝新忠;  吴力翔;  陆克义;  杨素云;  师晓丽;  胡婷婷
山西医科大学第一医院核医学科, 太原 030001
Author(s):
Kou Ying;  Liu Jianzhong;  Hao Xinzhong;  Wu Lixiang;  Lu Keyi;  Yang Suyun;  Shi Xiaoli;  Hu Tinging
Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
甲状腺肿瘤; 碘放射性同位素; 全身成像; 盆腔浓聚
Keywords:
Thyroid neoplasms; Iodine radioisotopes; Whole body imaging; Pelvic uptake
DOI:
10.3760/cma.j.issn 1673-4114.2014.01.004
摘要:
目的 了解分化型甲状腺癌患者对治疗后全身显像(Rx-WBS)盆腔131I明显浓聚情况及可能机制。方法 ①回顾性收集168例分化型甲状腺癌女性患者的资料(均有Rx.WBS图像)。②分析Rx-WBS图像特点,根据一定的纳入标准,最终纳入分析46例患者,并进行随访。结果 盆腔131I明显浓聚的46例(46处浓聚)患者中,6例同时存在2个可能的浓聚原因,2例目前浓聚原因不明。在50个导致盆腔131I浓聚的原因中,与子宫相关41个,与子宫外相关9个,分别为直肠3个、膀胱5个、卵巢巧克力囊肿1个。在41个与子宫相关的浓聚因素中,结合SPECT/CT定位、B超、CT及随访结果发现,子宫肌瘤18个、节育器9个、子宫内膜增厚2个、官腔积液3个、月经期7个、子宫内膜腺肌症1个、孕囊1个。结论 ①当女性甲状腺癌患者的Rx.WBS图像在盆腔子宫水平出现131I明显浓聚时,多与子宫相关,膀胱因素相对少见;当浓聚定位到子宫时,排除生理性摄取,多提示相关的妇科疾病,以子宫肌瘤多见。②膀胱、直肠所致的盆腔子宫水平131I明显浓聚有其自身特点,相对易区分。(3)SPECT/CT对定位子宫浓聚131I具有重要意义。
Abstract:
Objective To analyze and explore the possible mechanism for pelvic 131I uptake after 131I post treatment whole body scan (RX-WBS)in patients with differentiated thyroid cancer. Methods ① Data were retrospectively reviewed from 168 female patients with differentiated thyroid cancer (everyone has a RX-WBS). ② 46 patients were accepted by analyzing the characteristics of Rx- WBS and combing with some inclusion criteria, and then followed up. Results Among the 46 patients (46 positions accumulated 131I)with significant pelvic 13q uptake, 6 patients had two reasons leading to pelvic 131I uptake, and 2 patients had no specific reason. Among the 50 reasons for pelvic 131I uptake, 41 reasons related with uterus, 3 reasons related to rectum, 5 related to bladder and 1 related to ovarian chocolate cyst. Among the 41 reasons related to uterus, by combining the examinations of SPECT/CT, ultrasound, CT and the follow-up results, 18 were uterine leiomyomas, 9 were intrauterine devices, 2 were endometrial thickening, 3 were uterine cavity effusion, 7 were menstrual periods, 1 were uterine adenomyosis, 1 were gestational sac. Conclusions ① In the Rx-WBS of female, the significant pelvic 131I uptake is generally caused by uterus, but not bladder. And it usually means gynecological disease, especially uterine leiomyomas when excluding physiological factors. ② It is generally easy to differentiate bladder from rectum because they have different characteristic features of the pelvic 131I uptake. ③ SPECT/CT plays a very important role in locating 131I uptake in uterus.

参考文献/References:

[1] Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer[J]. World J Surg, 2006, 30(6):1088-1095.
[2] Hirata K, Shiga T, Kubota KC, et al. Radioiodine therapy for thyroid cancer depicted uterine leiomyoma[J]. Clin Nucl Med, 2009, 34(1):180-181.
[3] Elgazzar AH, Mahmoud AR, Abdel-dayem HM. Technetium-99m DTPA uptake in uterine leiomyoma[J]. Clin Nucl Med, 1988, 13(1):29-31.
[4] 罗琼,罗全勇,陆汉魁,等.甲状腺癌131I治疗后扫描胆囊显影1例[J].中国医学影像技术,2005,21(10):1551.
[5] Yang J, Codreanu I, Servaes S, et al. Elevated iodine uptake at autogenous bone graft harvest sites[J]. Clin Nucl Med, 2012, 37(9):901-903.
[6] Ahn BC, Lee SW, Lee J, et al. Pulmonary aspergilloma mimicking metastasis from papillary thyroid cancer[J]. Thyroid, 2011, 21(5):555-558.
[7] Triggiani V, Moschetta M, Giagulli VA, et al. Diffuse 131I lung uptake in bronchiectasis:a potential pitfall in the follow-up of differentiated thyroid carcinoma[J]. Thyroid, 2012, 22(12):1287-1290.
[8] Gargya A, Chua E. Focal bronchiectasis causing abnormal pulmonary radioiodine uptake in a patient with well-differentiated papillary thyroid carcinoma[J/OL]. Case Rep Endocrinol, 2012, 2012[2013-09-22]. http://www.hindawi.com/crim/endocrinology/2012/452758.
[9] Picolos MK, Habra M, Safdar A, et al. Inactive pulmonary tuberculosis mimicking metastasis from papillary thyroid carcinoma in diagnostic radioiodine whole-body scintigraphy[J]. Thyroid, 2005, 15(9):1105-1106.
[10] Matthern M, Staab E. I-131 localization in hematocolpos:a differential diagnosis consideration for pelvic I-131 uptake[J]. Clin Nucl Med, 2007, 32(8):659-660.
[11] Rachinsky I, Driedger A. Iodine-131 uptake in a menstruating uterus:value of SPECT/CT in distinguishing benign and metastatic iodine-positive lesions[J].Thyroid, 2007, 17(9):901-902.
[12] Leitha T, Staudenherz A. Frequency of diagnostic dilemmas in 131I whole body scanning[J]. Nuklearmedizin, 2003, 42(2):55-62.
[13] Song HJ, Xue YL, Xu YH, et al. Abnormal 131I uptake in a benign serous ovarian cystadenoma mimicking bladder physiological uptake[J]. Clin Nucl Med, 2012, 37(3):e59-60.
[14] Lakshmanan M, Reynolds JC, De Vecchio S, et al. Pelvic radioio-dine uptake in a rectal wall teratoma after thyroidectomy for papillary carcinoma[J]. J Nucl Med, 1992, 33(10):1848-1850.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[13]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[14]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
　Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[15]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
　Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[16]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
　Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[17]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
　Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[18]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
　HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[19]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
　YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
[20]董峰,周荫保.分化型甲状腺癌术后131I清甲效果的影响因素[J].国际放射医学核医学杂志,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]
　DONG Feng,ZHOU Yin-bao.Influencing factors of radioiodine ablation of posts-urgical thyroid remnants in differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]

备注/Memo

备注/Memo:
收稿日期:2013-09-22。
通讯作者:刘建中(Email:liujz.3@163.com)
更新日期/Last Update: 1900-01-01